Eli Lilly

LLY

Market cap $1T

WW International (NASDAQ:WW) on Thursday said its Weight Watchers platform is now available through Eli Lilly Co.'s (NYSE:LLY) LillyDirect digital health care platform, expanding access to branded GLP-1 weight-loss medications alongside clinical and behavioral support services.

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are seeing massive demand. Like all drugs, Mounjaro and Zepbound have time-limited patent protections.

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it's in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes has learned.

Eli Lilly has worked hard to diversify its pipeline. Three new acquisitions will further help decrease its exposure to its core market.

Eli Lilly will halve ​its originally planned investment of €2.3 ‌billion ($2.67 billion) in Germany, CEO Dave Ricks told the Handelsblatt business daily.

Over recent months, a striking pattern has emerged: major capital allocators are positioning around AI-driven biology and longevity.

Eli Lilly (NYSE:LLY | LLY Price Prediction) just grew revenue 55.5% in a single quarter while raising full-year guidance to $82 billion to $85 billion.

Buffett, as CEO of Berkshire Hathaway, delivered six decades of market-beating returns. Abel took over the CEO role in January and aims to follow the path traced by the investing giant.

Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.

Wells Fargo's chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at roughly 90 million prescriptions, calling the trend “here to stay” because it's prescribed, not faddish.